Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.

Rimonabant is a cannabinoid type 1 receptor (CB1) antagonist formerly used to treat obesity, but which was withdrawn from the market in late 2008 because of its association with psychiatric adverse effects such as depression and anxiety. Previously, we showed that a single dose of rimonabant produce...

Full description

Bibliographic Details
Main Authors: Horder, J, Browning, M, Di Simplicio, M, Cowen, P, Harmer, C
Format: Journal article
Language:English
Published: 2012
_version_ 1797058039181737984
author Horder, J
Browning, M
Di Simplicio, M
Cowen, P
Harmer, C
author_facet Horder, J
Browning, M
Di Simplicio, M
Cowen, P
Harmer, C
author_sort Horder, J
collection OXFORD
description Rimonabant is a cannabinoid type 1 receptor (CB1) antagonist formerly used to treat obesity, but which was withdrawn from the market in late 2008 because of its association with psychiatric adverse effects such as depression and anxiety. Previously, we showed that a single dose of rimonabant produced a negative bias on an emotional word memory task, in the absence of subjective mood effects. The present study investigated whether a similar effect on emotional processing could be seen after 7 days' daily treatment with rimonabant 20 mg, using a randomized, placebo-controlled, between-subjects design in healthy volunteers (final n = 21). In comparison with placebo, rimonabant induced a negative bias on a memory recognition task without producing a change in subjective mood. This raises the possibility that the depressogenic effects of rimonabant may be linked to emotional memory biases, and that such biases may be detectable in the absence of subjective mood changes. Investigating such effects could be useful in detecting adverse psychiatric effects of novel treatments.
first_indexed 2024-03-06T19:44:56Z
format Journal article
id oxford-uuid:21f583a2-964c-47c5-93ea-dc5a2b65d6ba
institution University of Oxford
language English
last_indexed 2024-03-06T19:44:56Z
publishDate 2012
record_format dspace
spelling oxford-uuid:21f583a2-964c-47c5-93ea-dc5a2b65d6ba2022-03-26T11:36:11ZEffects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:21f583a2-964c-47c5-93ea-dc5a2b65d6baEnglishSymplectic Elements at Oxford2012Horder, JBrowning, MDi Simplicio, MCowen, PHarmer, CRimonabant is a cannabinoid type 1 receptor (CB1) antagonist formerly used to treat obesity, but which was withdrawn from the market in late 2008 because of its association with psychiatric adverse effects such as depression and anxiety. Previously, we showed that a single dose of rimonabant produced a negative bias on an emotional word memory task, in the absence of subjective mood effects. The present study investigated whether a similar effect on emotional processing could be seen after 7 days' daily treatment with rimonabant 20 mg, using a randomized, placebo-controlled, between-subjects design in healthy volunteers (final n = 21). In comparison with placebo, rimonabant induced a negative bias on a memory recognition task without producing a change in subjective mood. This raises the possibility that the depressogenic effects of rimonabant may be linked to emotional memory biases, and that such biases may be detectable in the absence of subjective mood changes. Investigating such effects could be useful in detecting adverse psychiatric effects of novel treatments.
spellingShingle Horder, J
Browning, M
Di Simplicio, M
Cowen, P
Harmer, C
Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
title Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
title_full Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
title_fullStr Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
title_full_unstemmed Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
title_short Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
title_sort effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist rimonabant on emotional processing
work_keys_str_mv AT horderj effectsof7daysoftreatmentwiththecannabinoidtype1receptorantagonistrimonabantonemotionalprocessing
AT browningm effectsof7daysoftreatmentwiththecannabinoidtype1receptorantagonistrimonabantonemotionalprocessing
AT disimpliciom effectsof7daysoftreatmentwiththecannabinoidtype1receptorantagonistrimonabantonemotionalprocessing
AT cowenp effectsof7daysoftreatmentwiththecannabinoidtype1receptorantagonistrimonabantonemotionalprocessing
AT harmerc effectsof7daysoftreatmentwiththecannabinoidtype1receptorantagonistrimonabantonemotionalprocessing